Akari Therapeutics PLC


Prices are adjusted according to historical splits.

Akari Therapeutics PLC Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$22.26 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Akari Therapeutics PLC had its IPO on 2015-09-21 under the ticker symbol AKTX.

The company operates in the Healthcare sector and Biotechnology industry. Akari Therapeutics PLC has a staff strength of 9 employees.

Stock update

Shares of Akari Therapeutics PLC opened at $3.67 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $3.6 - $3.83, and closed at $3.68.

This is a +4.93% increase from the previous day's closing price.

A total volume of 14,070 shares were traded at the close of the day’s session.

In the last one week, shares of Akari Therapeutics PLC have increased by +10.18%.

Akari Therapeutics PLC's Key Ratios

Akari Therapeutics PLC has a market cap of $22.26 million, indicating a price to book ratio of 3.4316 and a price to sales ratio of 0.

In the last 12-months Akari Therapeutics PLC’s revenue was $0 with a gross profit of $0 and an EBITDA of $-18391610. The EBITDA ratio measures Akari Therapeutics PLC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Akari Therapeutics PLC’s operating margin was 0% while its return on assets stood at -141.94% with a return of equity of -365.06%.

In Q2, Akari Therapeutics PLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Akari Therapeutics PLC’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-0.33 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Akari Therapeutics PLC’s profitability.

Akari Therapeutics PLC stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.1103. Its price to sales ratio in the trailing 12-months stood at 0.

Akari Therapeutics PLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$11.37 million
Total Liabilities
$3.05 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Akari Therapeutics PLC ended 2023 with $11.37 million in total assets and $0 in total liabilities. Its intangible assets were valued at $11.37 million while shareholder equity stood at $8.33 million.

Akari Therapeutics PLC ended 2023 with $0 in deferred long-term liabilities, $3.05 million in other current liabilities, 593492.00 in common stock, $-210561421.00 in retained earnings and $0 in goodwill. Its cash balance stood at $8.15 million and cash and short-term investments were $8.15 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Akari Therapeutics PLC’s total current assets stands at $11.35 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.63 million and inventory worth $0.

In 2023, Akari Therapeutics PLC's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Akari Therapeutics PLC paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Akari Therapeutics PLC stock is currently trading at $3.68 per share. It touched a 52-week high of $1.61 and a 52-week low of $1.61. Analysts tracking the stock have a 12-month average target price of $2.75.

Its 50-day moving average was $3.89 and 200-day moving average was $5.85 The short ratio stood at 0.67 indicating a short percent outstanding of 0%.

Around 755.3% of the company’s stock are held by insiders while 1211.7% are held by institutions.

Frequently Asked Questions About Akari Therapeutics PLC

The stock symbol (also called stock or share ticker) of Akari Therapeutics PLC is AKTX

The IPO of Akari Therapeutics PLC took place on 2015-09-21

Similar Industry Stocks (Biotechnology)

Last Price
Vaibhav Global Ltd (VAIBHAVGBL)

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.


75/76 Wimpole Street, London, United Kingdom, W1G 9RT